Top Analysts Recommend 3 Strong Buy Stocks with Significant Upside

BridgeBio Pharma, Crinetics Pharmaceuticals, and UTZ Brands are the top stock picks according to analysts. BridgeBio Pharma has a 43.40% upside potential, while Crinetics Pharmaceuticals has a 167.86% upside potential. UTZ Brands has a 41.93% upside potential. TipRanks' Analyst Top Stocks tool shows a list of recently rated stocks by top-ranking analysts.

Title: Analysts Highlight Upside Potential in BridgeBio Pharma, Crinetics Pharmaceuticals, and Utz Brands

Analysts have identified BridgeBio Pharma, Crinetics Pharmaceuticals, and Utz Brands as top stock picks, each with significant upside potential. According to recent reports, BridgeBio Pharma has a 43.40% upside potential, while Crinetics Pharmaceuticals boasts a 167.86% upside potential. Utz Brands, on the other hand, has a 41.93% upside potential, as per TipRanks' Analyst Top Stocks tool.

BridgeBio Pharma, a biopharmaceutical company focused on genetic illnesses, has been reaffirmed with an Overweight rating by Piper Sandler analysts. The analysts cited the upcoming Phase 3 topline readout of the CALIBRATE study for the company's calcilytic medication encaleret, expected in the second half of 2025. The study, which includes 67 individuals with autosomal dominant hypocalcemia type 1 (ADH1), is anticipated to have a favorable outcome given the positive efficacy findings from the Phase 2b study [1].

Crinetics Pharmaceuticals, another biopharmaceutical company, has seen its stock performance highlighted by analysts. While specific details on its upside potential and analyst ratings are not provided in the source materials, its inclusion in the top picks suggests strong market sentiment.

Utz Brands, a snack food company, has had its stock price target reduced by Barclays to $16.00 from $17.00. Despite this reduction, Barclays maintained its Overweight rating and expressed confidence in the company's overall performance trajectory. The adjustment in the price target reflects a better alignment of earnings expectations with the phasing of investment spending and year-ago comparisons. The company recently reported its first-quarter earnings for 2025, meeting analyst expectations and surpassing revenue forecasts [2].

These developments provide investors with insights into the current performance and strategic direction of these companies. BridgeBio Pharma's focus on genetic illnesses and the potential of its calcilytic medication, along with Utz Brands' strong retail performance and strategic investments, make them compelling choices for investors seeking significant upside potential.

References
[1] https://finance.yahoo.com/news/piper-sandler-reaffirms-overweight-rating-082540666.html
[2] https://www.investing.com/news/analyst-ratings/barclays-lowers-utz-brands-stock-price-target-to-16-from-17-93CH-4114264